Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, February 15, 2020

The New-Generation Muscle Relaxant MPH-220 Dissolves Spasticity in Muscles After Cns Injury - a Promising Drug to Address Post-Stroke Spasticity

How many decades will pass before your hospital has this? I'm thinking never because your hospital incompetently has no employee whose sole job is to keep up-to-date on stroke research and create protocols from such research. Won't your children and grandchildren be glad when YOU DID NOTHING  to get stroke solved by removing your incompetent stroke hospital personnel? Starting with the board of directors.

The New-Generation Muscle Relaxant MPH-220 Dissolves Spasticity in Muscles After Cns Injury - a Promising Drug to Address Post-Stroke Spasticity





MPH-220 is a new-generation muscle relaxant targeting fast skeletal muscle myosin-2, while avoiding neurological, cardiac and respiratory adverse effects. MPH-220 is pharmacologically safe (non-toxic, non-mutagenic), and accumulates in skeletal muscles while its appearance in other tissues - including heart, esophageal and diaphragm samples - is minuscule and temporary. Its high metabolic stability combined with the accumulation in target tissues enables MPH-220 to reduce muscle force in rat hindleg by 50% after oral administration in an FDA-approved pharmacological formulation, which effect is maintained for more than 10 hours. The residual uninhibited Type 1 myosin-2 fraction is of high importance when considering that one major drawback of current centrally acting muscle relaxants is the total loss of muscle tone if the extremely narrow effective range is overdosed (“weak knee effect”). Moreover, MPH-220 relaxes spastic muscles in an animal muscle spasticity disease model. Two days after chemical lesions generated in the pyramidal tract, the animals exhibited unilateral deficits in over-ground locomotion due to spastic right forelimb. MPH-220 per os treatment relaxed the spastic limbs and the severe locomotion asymmetry normalized. These results provide evidence that the new-generation muscle relaxant has superior effects over current medications that have severe neurological and cardiovascular side effects. MPH-220 is therefore a promising anti-spasticity drug in nervous system injury etiologies.




To read this article in full you will need to make a payment

No comments:

Post a Comment